Liver Health Supplement Ampelopsis Grossedentata Vine Tea Extract Dihydromyricetin Dhm 98% Powder

• Customization: Available
• Certification: ISO, Halal
• Assay Method: HPLC-MS, HPLC
• Model NO.: NY035
• Application Form: Tablet, Capsule, Softgels, Tinctures, Liquids, Drops
• Application: Health Care Products, Medicine
• State: Powder
• Extract Source: Vine Tea
• Color: White Powder
• Lead Time: 5 Days
• Transport Package: 25kg/Drum
• Specification: 98%
• Trademark: Nutrayours/ OEM
• Origin: China
• HS Code: 1302199099
• Production Capacity: 3000kg/Year

Product Description

 

About this item

 

• 100% NATURAL PRODUCT: No artificial colors or flavors
• Verified herb identity, confirmed highest quality of raw herb and the extract
• Best natural sources of herbs and raw materials: Every vendor is carefully picked to meet our high standards
• Third-party lab tested, pure Dihydromyricetin

      Dihydromyricetin, also known as Dihydromyricetin (DMY or DHM) , is a dihydroflavonol flavonoid compound. it was first isolated in 1940 from the leaves of the snake grape, and again in 1996 from the stems and leaves of rattan tea, was renamed dihydromyricetin. dihydrogen arbutus pigment widely exists in many kinds of plants, includes grapes , myricaceae, cuckoo, gambogic , euphorbiaceae olive branch, , fabaceae, mountain lam and clethraceae among them with the most abundant content of grape vine snake genera plants, show tooth if snakes in the grape , cany tea) content as high as 37.4% to 38.5%.
     
Dihydromyricetin has various biological activities, including liver protection, antioxidant, antibacterial and so on. In addition, has been shown to be a potent dihydropyrimidase inhibitor, can activate autophagy by inhibiting mTOR signal, can further inhibit the formation of mTOR complex (mTORC1/2) . These properties make dihydromyricetin have potential applications in scientific research and medicine. 
Keywords:Dihydromyricetin, Fujian thein, leucopterin, dihydromyricetin,ophiopsin

About us

* The statements in this section have not been evaluated by the FDA or EFSA.

References

    1.Sun Y, Liu S, Yang S, Chen C, Yang Y, Lin M, Liu C, Wang W, Zhou X, Ai Q, Wang W, Chen N.Front Pharmacol. 2022 Jan 18;12:794563. doi: 10.3389/fphar.2021.794563. eCollection 2021.PMID: 35115939 
    2.Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, Lu H, Wang S.Pharmacol Res. 2021 Sep;171:105767. doi: 10.1016/j.phrs.2021.105767. Epub 2021 Jul 14.PMID: 34273490

    3.Wang Z, Cao Z, Yue Z, Yang Z.Front Endocrinol (Lausanne). 2023 Sep 4;14:1216907. doi: 10.3389/fendo.2023.1216907. eCollection 2023.PMID: 37732125 
    4.Xie J, Zhang T, Li P, Wang D, Liu T, Xu S.Drug Des Devel Ther. 2022 Sep 11;16:3071-3085. doi: 10.2147/DDDT.S378786. eCollection 2022.PMID: 36118165
    5.Liu X, Li Y, Chen S, Yang J, Jing J, Li J, Wu X, Wang J, Wang J, Zhang G, Tang Z, Nie H.Phytomedicine. 2023 Jul;115:154756. doi: 10.1016/j.phymed.2023.154756. Epub 2023 Mar 12.PMID: 37130481